Lin BioScience, Inc. (6696.TWO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Zhengqi Wang M.B.A., Ph.D. | President, CSO & Director | -- | -- | -- |
| Ms. Serena Chen | Chief Financial Officer | -- | -- | -- |
| Ms. Hongwei Chen | Chief Operating Officer | -- | -- | -- |
Lin BioScience, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available